Literature DB >> 21720388

The association of phosphoinositide 3-kinase enhancer A with hepatic insulin receptor enhances its kinase activity.

Chi Bun Chan1, Xia Liu, Kunyan He, Qi Qi, Dae Y Jung, Jason K Kim, Keqiang Ye.   

Abstract

Dysfunction of hepatic insulin receptor tyrosine kinase (IRTK) causes the development of type 2 diabetes. However, the molecular mechanism regulating IRTK activity in the liver remains poorly understood. Here, we show that phosphoinositide 3-kinase enhancer A (PIKE-A) is a new insulin-dependent enhancer of hepatic IRTK. Liver-specific Pike-knockout (LPKO) mice display glucose intolerance with impaired hepatic insulin sensitivity. Specifically, insulin-provoked phosphoinositide 3-kinase/Akt signalling is diminished in the liver of LPKO mice, leading to the failure of insulin-suppressed gluconeogenesis and hyperglycaemia. Thus, hepatic PIKE-A has a key role in mediating insulin signal transduction and regulating glucose homeostasis in the liver.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720388      PMCID: PMC3147257          DOI: 10.1038/embor.2011.108

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  24 in total

1.  Evidence from a large U.K. family collection that genes influencing age of onset of type 2 diabetes map to chromosome 12p and to the MODY3/NIDDM2 locus on 12q24.

Authors:  Steven Wiltshire; Timothy M Frayling; Christopher J Groves; Jonathan C Levy; Graham A Hitman; Mike Sampson; Mark Walker; Stephan Menzel; Andrew T Hattersley; Lon R Cardon; Mark I McCarthy
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

2.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

3.  5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside.

Authors:  S N Jakobsen; D G Hardie; N Morrice; H E Tornqvist
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

4.  Hormonal regulation of mouse fatty acid synthase gene transcription in liver.

Authors:  J D Paulauskis; H S Sul
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

5.  Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction.

Authors:  M D Michael; R N Kulkarni; C Postic; S F Previs; G I Shulman; M A Magnuson; C R Kahn
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

6.  GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins.

Authors:  Chunzhi Xia; Wenbin Ma; Lewis Joe Stafford; Chengyu Liu; Liming Gong; James F Martin; Mingyao Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

Review 7.  Fasting hyperglycemia: etiology, diagnosis, and treatment.

Authors:  John P Sheehan
Journal:  Diabetes Technol Ther       Date:  2004-08       Impact factor: 6.118

8.  PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion.

Authors:  Jee-Yin Ahn; Rong Rong; Todd G Kroll; Erwin G Van Meir; Solomon H Snyder; Keqiang Ye
Journal:  J Biol Chem       Date:  2004-02-03       Impact factor: 5.157

9.  PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis.

Authors:  Rong Rong; Jee-Yin Ahn; Honglian Huang; Eiichiro Nagata; Daniel Kalman; Judith A Kapp; Jiancheng Tu; Paul F Worley; Solomon H Snyder; Keqiang Ye
Journal:  Nat Neurosci       Date:  2003-10-05       Impact factor: 24.884

10.  Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.

Authors:  Chi Bun Chan; Xia Liu; Dae Young Jung; John Y Jun; Hongbo R Luo; Jason K Kim; Keqiang Ye
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

View more
  9 in total

1.  What we have learnt about PIKE from the knockout mice.

Authors:  Chi Bun Chan; Keqiang Ye
Journal:  Int J Biochem Mol Biol       Date:  2011-06-07

2.  Tumor Necrosis Factor-α Promotes Phosphoinositide 3-Kinase Enhancer A and AMP-Activated Protein Kinase Interaction to Suppress Lipid Oxidation in Skeletal Muscle.

Authors:  Margaret Chui Ling Tse; Oana Herlea-Pana; Daniel Brobst; Xiuying Yang; John Wood; Xiang Hu; Zhixue Liu; Chi Wai Lee; Aung Moe Zaw; Billy K C Chow; Keqiang Ye; Chi Bun Chan
Journal:  Diabetes       Date:  2017-04-12       Impact factor: 9.461

3.  Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity.

Authors:  S Zhang; Q Qi; C B Chan; W Zhou; J Chen; H R Luo; C Appin; D J Brat; K Ye
Journal:  Cell Death Differ       Date:  2015-05-22       Impact factor: 15.828

4.  Fyn regulates adipogenesis by promoting PIKE-A/STAT5a interaction.

Authors:  Margaret Chui Ling Tse; Xia Liu; Seran Yang; Keqiang Ye; Chi Bun Chan
Journal:  Mol Cell Biol       Date:  2013-02-25       Impact factor: 4.272

5.  PIKE is essential for oligodendroglia development and CNS myelination.

Authors:  Chi Bun Chan; Xia Liu; Lixia Zhao; Guanglu Liu; Chi Wai Lee; Yue Feng; Keiqang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

6.  Essential role of PIKE GTPases in neuronal protection against excitotoxic insults.

Authors:  Chi Bun Chan; Yongjun Chen; Xia Liu; Ligia Papale; Andrew Escayg; Lin Mei; Keqiang Ye
Journal:  Adv Biol Regul       Date:  2012-01

7.  Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.

Authors:  Q Qi; K He; X Liu; C Pham; C Meyerkord; H Fu; K Ye
Journal:  Oncogene       Date:  2012-03-26       Impact factor: 9.867

Review 8.  Phosphoinositide 3-kinase enhancer (PIKE) in the brain: is it simply a phosphoinositide 3-kinase/Akt enhancer?

Authors:  Chi Bun Chan; Keqiang Ye
Journal:  Rev Neurosci       Date:  2012-01-26       Impact factor: 4.353

Review 9.  The roles of PIKE in tumorigenesis.

Authors:  Qi Qi; Keqiang Ye
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.